Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun 15;66(12):6111-7.
doi: 10.1158/0008-5472.CAN-05-4198.

Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients

Kazuo Koyanagi  1 , Takuji Mori, Steven J O'Day, Steve R Martinez, He-Jing Wang, Dave S B Hoon
Affiliations

Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients

Kazuo Koyanagi et al. Cancer Res. .

Abstract

Although previous studies have separately shown the utility of circulating tumor cells (CTC) or cell-free tumor-related DNA in blood of cancer patients, there has been no investigation of their association and/or the prognostic value of combining these assessments. To date, the true source of tumor-related DNA in serum remains unknown. We hypothesized that CTC is a possible origin of serum tumor-related methylated DNA and their combination can predict disease outcome. To test this hypothesis, we obtained matched pairs of peripheral blood lymphocytes and serum specimens simultaneously from 50 American Joint Committee on Cancer stage IV melanoma patients before administration of biochemotherapy. Peripheral blood leukocytes were analyzed for three mRNA markers of CTC: MART-1, GalNAc-T, and MAGE-A3. Sera were analyzed for two methylated DNA markers: RASSF1A and RAR-beta2. CTC were detected in 13 of 15 (86%) patients with serum tumor-related methylated DNA and only in 13 of 35 (37%) patients without methylated DNA (P = 0.001). The number of CTC markers detected significantly correlated with methylated DNA (P = 0.008). CTC and methylated DNA were significantly correlated with biochemotherapy-treated patients' outcome. Patients with both CTC and methylated DNA showed significantly poorer response to biochemotherapy (P = 0.02) and worse time to progression and overall survival (P = 0.009 and 0.02, respectively). The correlation between CTC and serum tumor-related methylated DNA and the significant effect of this correlation on disease outcome indicate that a composite molecular assessment in blood may be a useful determinant of disease status and efficacy of systemic therapy for melanoma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier curves of time to progression (left ) and overall survival (right) based on CTC detection.
Figure 2
Figure 2
Kaplan-Meier curves of time to progression (left) and overall survival (right) based on serum methylated DNA detection.
Figure 3
Figure 3
Kaplan-Meier curves of time to progression (left) and overall survival (right) based on CTC and serum methylated DNA detection.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635–48. - PubMed
    1. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6. New York: Springer-Verlag; 2002.
    1. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999;91:1113–24. - PubMed
    1. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science. 1997;278:1054–9. - PubMed
    1. Taback B, Hoon DS. Circulating nucleic acids in plasma and serum: past, present and future. Curr Opin Mol Ther. 2004;6:273–8. - PubMed

Publication types

MeSH terms

Substances